Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function.
A study was carried out to determine the efficacy and long-term safety of dantrolene in treating stroke patients with spasticity limiting rehabilitation. Fifteen of the 18 patients studied experienced reduction in spasticity and clinical improvement after treatment with dantrolene sodium for 6 weeks. Fourteen of these patients participated in a 6-week, double-blind, placebo-controlled study. The 5 patients who continued to receive dantrolene did not experience clinical deterioration. However, the 9 patients given placebo noted increased deficits. Seven asked that the blind be broken and chose to resume dantrolene therapy. After 6 weeks, 13 of the 14 patients elected to continue on dantrolene (average dose 165.4 mg/day). All continued to improve. Side-effects were generally mild and transient. Although these patients took other drugs concomitantly, no drug interactions were reported.